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Abstract We report a fatal intravenous ioversol
administration in a 60-year old male patient. Although the
introduction of new low-osmolar non-ionogenic contrast
media with a more favourable efficacy-toxicity balance has
diminished the side-effects significantly, everyone involved
in radiodiagnostic procedures should be aware of the po-
tential life-threatening effects. Especially patients with risk
factors for side-effects should be monitored carefully.
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Introduction
For several decades, organic iodinated contrast media have
been used for diagnostic radiologic imaging purposes.
Because of the absorption difference of X-rays by the
iodine-molecule and surrounding tissues, radiographic
visualisation of structures is possible. Although new com-
pounds with a more favourable efficacy-toxicity balance
have been introduced, severe and life-threatening side-ef-
fects are still reported.
We present a male patient with a fatal cardiac arrest
after intravenous ioversol administration.
Case description
A 60-year-old man, with a history of regulated diabetes
mellitus type II and hypertension, was referred for an
abdominal contrast-enhanced CT-scan, because of pre-
surgical staging of a rectal carcinoma His medication
consisted of metformin and a thiazide diuretic. There was
no history of allergic reactions.
After ioversol 350, 100 ml had been administered intra-
venously, the patient complained of headache and nausea.
Subsequently, he lost consciousness with discoloration of his
skin to red-purple. Immediate basic life support was started.
On arrival of the medical emergency team, patient was found
in pulseless electrical activity. During endotracheal intubation
no signs of glottis edema were noticed. Ventricular fibrillation
developed for which (unsuccessful) external electrical defi-
brillation was performed. After 40 min of cardiopulmonary
resuscitation with repeated doses of epinephrine, clemastine,
atropine, and amiodarone, with concomitant dexamethasone,
calcium, theophylline, transcutaneous pacing and intracardial
epinephrine, the transthoracic echocardiogram yielded car-
diac standstill without ventricular dilatation. It was then
decided to cease resuscitation.
An autopsy found, besides the rectal carcinoma without
lymph node metastasis, benign adrenal and prostatic
hyperplasia concentric left ventricular hypertrophy.
Discussion
Ioversol, used in the present case, is a low-osmolar
nonionic monomeric contrast medium, with a relatively
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low risk of (severe) side-effects. According to the
information from the manufacturer, anaphylactoid reac-
tions occur in 0.1–1% of cases, life-threatening in less
than 0.01% [1]. The Netherlands Pharmacovigilance
Centre (LAREB) received no report of pseudo-allergic
reactions to ioversol administration since its registration
in 2001, although one report of severe dyspnoe was
found [2].
Intravenous administration of low-osmolar contrast
media is associated with side-effects in 2.1% of patients,
being mild in 1.2%, moderate in 0.9%, and severe in 0.01%
[3]. For the 52% of patients in this study that had risk
factors for adverse effects, not being defined in detail, the
side effect rate was 2.7%.
The toxicity of contrast media is determined by the
intrinsic toxicity and the osmolarity of the medium.
The intrinsic toxicity is attributed to the ability to bind to
biological macro-molecules, such as proteins [4]. Since
non-ionic and dimeric contrast molecules bind to proteins
to a lesser extent than ionic and monomeric contrast mol-
ecules, contrast media with non-ionic dimeric molecules
(like ioversol) are less toxic.
Life-threatening hypersensitivity reactions have been
reported on intravenous administration of iodinated con-
trast media [5]. Most frequent symptoms are fever, pur-
pura, skin reactions, cardiovascular collapse (like in the
present case), convulsions, dyspnoe, renal impairment,
pseudo-allergic and/or anaphylactoid reactions [1]. In
contrast to initial exposure, clinically manifest IgE-reac-
tions arise at renewed exposure to the allergenic agent.
Therefore, anaphylactic reactions to iodinated contrast
media are specified as non-allergic anaphylactic or
anaphylactoı¨d reactions. The clinical symptoms, however,
of allergic and non-allergic anaphylactic reactions are
similar [6].
Several risk factors are identified for the occurrence of
side-effects of iodinated contrast media [1] (Table 1); in
the present case, the patient had the following risk factors:
diabetes, cardiovascular disease and co-medication (met-
formine). Recommendations for the prevention of renal
side-effects are well known and include the preferred use
of low-osmolar over high-osmolar contrast media,
avoidance of the administration of high doses, sufficient
hydration, and prophylactic administration of antioxidants
in order to disable the action of cytotoxic oxygen free
radicals causing ischemic renal injury. Moreover, cal-
cium-channel blockers can be considered for their positive
effects on renal haemodynamics and their cytoprotective
effects on renal cells. Furthermore, pre-heating of the
contrast fluid before administration decreases its viscosity,
reducing side-effects as well [7].
Conclusion
In the present case, ioversol administration evidently
caused the death of this patient. Despite adequate inter-
vention of the medical emergency team, cardiopulmonary
resuscitation was not successful. Although the introduction
of low-osmolar noniogenic contrast media has diminished
the side-effects significantly, every radiologist and others
involved in radiodiagnostic procedures should be aware of
the potential life-threatening effects. Especially patients
with risk factors for side-effects, including cardiovascular
disease, diabetes, renal impairment, and particular co-
medication, should be monitored carefully with an ade-
quately organized and operating medical emergency team
on duty. Appropriate guidelines for the treatment of acute
adverse reactions and equipment available in the room
where the contrast medium is given, are provided by the
Contrast Media Safety Committee of the European Society
of Urogenital Radiology and the American College of
Radiology [8, 9].
Table 1 Risk factors for side-effects of contrast media
Previous reactions on iodinated contrast media
Positive allergic anamnesis
High osmolar contrast medium
High dose contrast medium (>100 ml)
Intra-arterial injection
Dehydration





Nephrotoxic co-medication (e.g. metformine, vasopressor drugs,
nonsteroidal anti-inflammatory drugs, diuretics, aminoglycosides)
Co-medication (neuroleptic drugs, antidepressants, analeptic drugs,
MAO-inhibitors)
Hyperthyroidism
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